- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02822443
Improve: Integrating Emotion Focused Components Into Psychological Therapy (Improve)
The Impact of Integrating Emotion Focused Components Into Psychological Therapy
Study Overview
Status
Detailed Description
Background:
"General Psychotherapy" postulates an ongoing process of including all interventions and concepts relevant for a domain, be they from other approaches to psychotherapy or concepts from basic science. "Psychological Therapy" (PT) is a therapeutic approach largely corresponding to the ideas of General Psychotherapy. It draws mainly on empirically validated interventions from Cognitive Behavior Therapy (CBT) and is based on concepts with a strong basis in academic psychology and neighboring fields. PT is based on explicit individual case conceptualization, reference to general therapeutic factors, and an explicit prescriptive concept for building and maintaining the therapeutic relationship. However the range of emotion-related interventions commonly used in PT is limited when compared with an approach like Emotion Focused Therapy (EFT). EFT appears thus as a suitable complement and enrichment to PT as commonly practiced. However, effects of integrating EFT-based interventions in a way that is close to common integrative practice have not yet been studied.
Objective:
To compare the efficacy of two treatment-as-usual (TAU) conditions: TAU with integration of EFT components and TAU with focus on self-regulation (SR).
Methods:
In Switzerland, a randomized-controlled trail will be carried out in secondary care, comparing the efficacy of TAU - EFT and TAU - SR for adults with major depressive disorder, anxiety disorder or adjustment disorder. Respondents will be followed until 36 months after end of therapy (measures will be taken at baseline, after 8 and after 16 weeks, at the end of therapy after 25 weeks, 6 months, 12 months and 36 months follow-up).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bern, Switzerland
- University of Bern
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Major Depressive Disorder, Anxiety Disorder or Adjustment Disorder according to DSM-IV as main diagnosis
- Minimum age of 18 years
- Mastery of the German language for being able to undergo a psychotherapy in German
- Written informed consent to participate voluntary in the study
Exclusion Criteria:
- Acute suicidality or immediate threats of self-harm
- Diagnosis or history of a psychotic disorder
- Mood incongruent psychotic symptoms
- Bipolar disorder
- Comorbid chronic organic disorder
- Substance use disorder as a main diagnosis
- Indication for a residential treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TAU - EFT
This arm integrates emotion focused components (EFT; Greenberg, 2010) into psychological therapy (PT) as treatment-as-usual (TAU), aiming at clarifying and transforming maladaptive emotions.
25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on emotion-focused interventions.
|
Behavioral: Psychological therapy (PT) as TAU with integrated emotion focused components (TAU - EFT)
25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on emotion-focused interventions.
|
Experimental: TAU - SR
This arm focuses on the training of self-regulation strategies (SR; Carver & Scheier, 2000) in the context of psychological therapy (PT) as treatment-as-usual (TAU).
25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on self-regulation without emotion-focused interventions.
|
25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on self-regulation without emotion-focused interventions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in symptom impairment measured by the Brief Symptom Inventory (BSI; Franke, 2000)
Time Frame: After 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
After 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
Change from baseline in depressive symptoms measured by the Beck Depression Inventory (BDI-II; Hautzinger et al., 2006)
Time Frame: After 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
After 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
Change from baseline in anxiety symptoms measured by the Beck Anxiety Inventory (BAI; Ehlers & Margraf, 2007)
Time Frame: After 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
After 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Severity of panic disorder and agoraphobia with the Panic and Agoraphobia Scale (PAS; Bandelow, 1997)
Time Frame: Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
Severity of social phobia measured by the Social Phobia Scale SPS; Stangier et al., 1999)
Time Frame: Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
Severity of social interaction anxiety measured by the Social Interaction Anxiety Scale (SIAS; Stangier et al., 1999)
Time Frame: Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
Severity of anxiety symptoms measured by the Questionnaire for General Anxiety Disorder (GAD-7; Spitzer et al., 2006)
Time Frame: Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
Psychological well-being measured with the WHO Well-Being Index (WHO-5; Henkel et al., 2004)
Time Frame: Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
Health-related quality of life measured with the Short Form Healthy Survey (SF-12; Gandek et al., 1998)
Time Frame: Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
Motivational schemata measured by the Questionnaire for Analysis of Motivational Schemata (FAMOS; grosse Holtforth & Grawe, 2000)
Time Frame: Baseline, end of therapy after 25 weeks
|
Baseline, end of therapy after 25 weeks
|
Motivational incongruence measured by the Incongruence Questionnaire (K-INK; grosse Holtforth et al., 2003)
Time Frame: Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
Interpersonal problems measured by the Inventory of Interpersonal Problems (IIP-32; Thomas et al., 2011)
Time Frame: Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
Personality structure measured by the Operationalized Psychodynamic Diagnosis Structure Questionnaire (OPD-SFK; Ehrenthal et al., 2012)
Time Frame: Baseline, end of therapy after 25 weeks
|
Baseline, end of therapy after 25 weeks
|
Personality traits measured by the Inventory of Personality Organization (IPO-16; Zimmermann et al., 2013)
Time Frame: Baseline
|
Baseline
|
Ambivalence over emotional expressiveness measured by the Ambivalence over the Expression of Emotion Scale (AVEX; Trachsel et al., 2010)
Time Frame: Baseline, end of therapy after 25 weeks
|
Baseline, end of therapy after 25 weeks
|
Emotional competency measured by the Questionnaire for the self-assessment of emotional competencies (SEK-27; Berking & Znoj, 2008)
Time Frame: Baseline, end of therapy after 25 weeks
|
Baseline, end of therapy after 25 weeks
|
Generalized expectancies for negative mood regulation measured by the Negative Mood Regulation Scale (NMR-SF; Pfeiffer et al., 2013)
Time Frame: Baseline, end of therapy after 25 weeks
|
Baseline, end of therapy after 25 weeks
|
Psychological flexibility measured by the Acceptance and Action Questionnaire (Fragebogen zu Akzeptanz und Handeln; FAH-II; Gloster et al., 2013)
Time Frame: Baseline, end of therapy after 25 weeks
|
Baseline, end of therapy after 25 weeks
|
General self-efficacy measured by the General Self-Efficacy Scale (SWE; Schwarzer & Jerusalem, 1999)
Time Frame: Baseline, end of therapy after 25 weeks
|
Baseline, end of therapy after 25 weeks
|
Therapy evaluation and outcome expectancies measured by the Patient Questionnaire on Therapy Expectation and Evaluation (PATHEV; Schulte, 2005)
Time Frame: Baseline
|
Baseline
|
Social desirability measured by the Balanced Inventory of Desirable Responding (BIDR-K; Winkler et al., 2006)
Time Frame: Baseline
|
Baseline
|
Client satisfaction measured by the Brief Global Measure of Client Satisfaction (ZUF-8; Schmidt & Wittmann, 2002)
Time Frame: After 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
After 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
External assessment of interpersonal personality measured by the Impact Message Inventory (IMI-R; Caspar et al. 2002)
Time Frame: Baseline, end of therapy after 25 weeks
|
Baseline, end of therapy after 25 weeks
|
External assessment of resources measured by the Bernese Inventory of Resources (REF-F and REF-T; Tröske, 2000)
Time Frame: Baseline, end of therapy after 25 weeks
|
Baseline, end of therapy after 25 weeks
|
External assessment of positive interpersonal qualities measured by the Inventory of Interpersonal Strengths (IIS; Hatcher & Rogers, 2012)
Time Frame: Baseline, end of therapy after 25 weeks
|
Baseline, end of therapy after 25 weeks
|
Goal attainment measured by the Goal Attainment Scaling (GAS; Kirusek, 1994)
Time Frame: After 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
After 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
|
Regular quality monitoring with the Bern Post Session Report, Patient and Therapist Version (BPSR-P/T; Flückiger et al. 2010)
Time Frame: Weekly until 25 weeks
|
Weekly until 25 weeks
|
Symptom impairment measured by the Symptom Checklist (SCL-9; Bogerts et al., 2001)
Time Frame: Weekly until 25 weeks
|
Weekly until 25 weeks
|
Implicit motives measured by the Picture-Story-Exercise - Online Version (PSE-O: Bernecker & Jobst, 2013)
Time Frame: Baseline, end of therapy after 25 weeks
|
Baseline, end of therapy after 25 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Franz Caspar, Prof. PhD, University of Bern, Switzerland
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SNF100019_159425 /1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unipolar Depression
-
Brown UniversityCompletedMild-moderate Unipolar Depression; Persistent Negative AffectUnited States
-
University GhentUniversity Hospital, GhentCompleted
-
University Hospital, MontpellierAssistance Publique - Hôpitaux de Paris; University Hospital, Clermont-Ferrand and other collaboratorsRecruitingUnipolar Depressed Outpatients | Mild Severity | Without Psychotic FeaturesFrance
-
Massachusetts General HospitalTakedaTerminatedDepressive Disorder | Depression | Major Depression | Depression, UnipolarUnited States
-
University of OxfordNational Institute for Health Research, United KingdomNot yet recruiting
-
The University of New South WalesUniversity of SydneyCompleted
-
University of AarhusTerminatedUnipolar DepressionDenmark
-
Norwegian Institute of Public HealthCompleted
-
University of Medicine and Pharmacy at Ho Chi Minh...Unknown
-
University Hospital TuebingenGerman Federal Ministry of Education and Research; Universität TübingenUnknown